Cardiff Oncology Inc — Cash Flow (NASDAQ:CRDF) | MetaTrader

Open full chart

Financials

Overview Отчетность Statistics Dividends

Quarterly Annual

Cash from operating activities -16.31 M-23.04 M-33.82 M-30.89 M-37.69 M-37.92 M -37.92 M Cash from investing activities -211.88 K-131.45 M38.15 M36.2 M13.73 M1.34 M 1.34 M Cash from financing activities 137.31 M35.45 M75 K053.78 M2.58 M 2.58 M Free cash flow -16.53 M-23.25 M-34.83 M-31.47 M-37.77 M-37.97 M -37.92 M

Новости

Cardiff Oncology kazancı $0,08 ile beklentilere göre daha iyi, kâr ise beklentilere göre yüksek

Cardiff Oncology earnings beat by $0.08, revenue topped estimates

H.C. Wainwright, Cardiff Oncology hissesi için Al tavsiyesini 10 dolar hedefle yineledi

H.C. Wainwright reiterates Buy rating on Cardiff Oncology stock at $10

Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript

Why Did Cardiff Oncology Stock Plunge On Tuesday? - Cardiff Oncology (NASDAQ:CRDF)

Cardiff Oncology hisseleri Faz 2 denemesi veri güncellemesinden sonra düşüşe geçti

Cardiff Oncology stock tumbles after Phase 2 trial data update

Cardiff Oncology, liderlik değişimi sırasında geçici CEO atadı

Cardiff Oncology kanser ilacı için olumlu faz 2 verilerini açıkladı

Cardiff Oncology appoints interim CEO amid leadership transition

Cardiff Oncology reports positive phase 2 data for cancer drug